Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management
- PMID: 23114995
- DOI: 10.1007/s10741-012-9364-5
Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management
Abstract
According to the current WHO classification of cardiomyopathies, myocarditis is an inflammatory disease of the myocardium and is diagnosed by endomyocardial biopsy using established histological, immunological and immunohistochemical criteria; it may be idiopathic, infectious or autoimmune and may heal or lead to dilated cardiomyopathy (DCM). DCM is characterized by dilatation and impaired contraction of the left or both ventricles; it may be idiopathic, familial/genetic, viral and/or immune. The diagnosis of DCM requires exclusion of known, specific causes of heart failure, including coronary artery disease. On endomyocardial biopsy, there is myocyte loss, compensatory hypertrophy, fibrous tissue and immunohistochemical findings consistent with chronic inflammation (myocarditis) in 30-40 % of cases. In a patient subset, myocarditis and DCM represent the acute and chronic stages of an inflammatory disease of the myocardium, which can be viral, post-infectious immune or primarily organ-specific autoimmune. Here, we review the clinical presentation, etiopathogenetic diagnostic criteria, and management of immune-mediated and autoimmune myocarditis.
Similar articles
-
Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy.Autoimmunity. 2008 Feb;41(1):35-45. doi: 10.1080/08916930701619235. Autoimmunity. 2008. PMID: 18176863 Review.
-
Inflammatory dilated cardiomyopathy (DCMI).Herz. 2005 Sep;30(6):535-44. doi: 10.1007/s00059-005-2730-5. Herz. 2005. PMID: 16170686 Review.
-
Anti-heart autoantibodies in familial dilated cardiomyopathy.Autoimmunity. 2008 Sep;41(6):462-9. doi: 10.1080/08916930802031546. Autoimmunity. 2008. PMID: 18781472 Review.
-
Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy.Autoimmunity. 2001;34(3):199-204. doi: 10.3109/08916930109007385. Autoimmunity. 2001. PMID: 11908778 Review.
-
Genetically determined myocarditis: clinical presentation and immunological characteristics.Curr Opin Cardiol. 2008 May;23(3):219-26. doi: 10.1097/HCO.0b013e3282fbf572. Curr Opin Cardiol. 2008. PMID: 18382209 Review.
Cited by
-
GSK3 modulation in acute lung injury, myocarditis and polycystic kidney disease-related aneurysm.Biochim Biophys Acta Mol Cell Res. 2020 Nov;1867(11):118798. doi: 10.1016/j.bbamcr.2020.118798. Epub 2020 Jul 18. Biochim Biophys Acta Mol Cell Res. 2020. PMID: 32693109 Free PMC article. Review.
-
Inhibition of microRNA-155 ameliorates experimental autoimmune myocarditis by modulating Th17/Treg immune response.J Mol Med (Berl). 2016 Sep;94(9):1063-79. doi: 10.1007/s00109-016-1414-3. Epub 2016 Apr 6. J Mol Med (Berl). 2016. PMID: 27052830
-
Immunomodulatory Therapy for Giant Cell Myocarditis: A Narrative Review.Cureus. 2023 Jun 14;15(6):e40439. doi: 10.7759/cureus.40439. eCollection 2023 Jun. Cureus. 2023. PMID: 37456487 Free PMC article. Review.
-
Dilated cardiomyopathy: the complexity of a diverse genetic architecture.Nat Rev Cardiol. 2013 Sep;10(9):531-47. doi: 10.1038/nrcardio.2013.105. Epub 2013 Jul 30. Nat Rev Cardiol. 2013. PMID: 23900355 Review.
-
COVID-19-A Theory of Autoimmunity Against ACE-2 Explained.Front Immunol. 2021 Mar 23;12:582166. doi: 10.3389/fimmu.2021.582166. eCollection 2021. Front Immunol. 2021. PMID: 33833750 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical